Llewellyn E Jalbert
Overview
Explore the profile of Llewellyn E Jalbert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
1075
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Luks T, Richmond McKnight T, Jalbert L, Williams A, Neill E, Lobo K, et al.
Transl Oncol
. 2018 Jun;
11(4):941-949.
PMID: 29883968
The goal of this research was to elucidate the relationship between WHO 2016 molecular classifications of newly diagnosed, nonenhancing lower grade gliomas (LrGG), tissue sample histopathology, and magnetic resonance (MR)...
2.
Hayes J, Yu Y, Jalbert L, Mazor T, Jones L, Wood M, et al.
Neuro Oncol
. 2017 Oct;
20(5):632-641.
PMID: 29077933
Background: Rare multicentric lower-grade gliomas (LGGs) represent a unique opportunity to study the heterogeneity among distinct tumor foci in a single patient and to infer their origins and parallel patterns...
3.
Mazor T, Chesnelong C, Pankov A, Jalbert L, Hong C, Hayes J, et al.
Proc Natl Acad Sci U S A
. 2017 Sep;
114(40):10743-10748.
PMID: 28916733
mutation is the earliest genetic alteration in low-grade gliomas (LGGs), but its role in tumor recurrence is unclear. Mutant IDH1 drives overproduction of the oncometabolite d-2-hydroxyglutarate (2HG) and a CpG...
4.
Jalbert L, Elkhaled A, Phillips J, Neill E, Williams A, Crane J, et al.
Sci Rep
. 2017 Mar;
7:44792.
PMID: 28327577
Infiltrating low grade gliomas (LGGs) are heterogeneous in their behavior and the strategies used for clinical management are highly variable. A key factor in clinical decision-making is that patients with...
5.
Neill E, Luks T, Dayal M, Phillips J, Perry A, Jalbert L, et al.
J Neurooncol
. 2017 Jan;
132(1):171-179.
PMID: 28124178
Low-grade gliomas can vary widely in disease course and therefore patient outcome. While current characterization relies on both histological and molecular analysis of tissue resected during surgery, there remains high...
6.
Jalbert L, Neill E, Phillips J, Lupo J, Olson M, Molinaro A, et al.
Neuro Oncol
. 2016 Feb;
18(8):1169-79.
PMID: 26911151
Background: Patients with low-grade glioma (LGG) have a relatively long survival, and a balance is often struck between treating the tumor and impacting quality of life. While lesions may remain...
7.
Park I, Mukherjee J, Ito M, Chaumeil M, Jalbert L, Gaensler K, et al.
Cancer Res
. 2014 Oct;
74(23):7115-24.
PMID: 25320009
Recent findings show that exposure to temozolomide (TMZ), a DNA-damaging drug used to treat glioblastoma (GBM), can suppress the conversion of pyruvate to lactate. To understand the mechanistic basis for...
8.
Johnson B, Mazor T, Hong C, Barnes M, Aihara K, McLean C, et al.
Science
. 2013 Dec;
343(6167):189-193.
PMID: 24336570
Tumor recurrence is a leading cause of cancer mortality. Therapies for recurrent disease may fail, at least in part, because the genomic alterations driving the growth of recurrences are distinct...
9.
Elkhaled A, Jalbert L, Phillips J, Yoshihara H, Parvataneni R, Srinivasan R, et al.
Sci Transl Med
. 2012 Jan;
4(116):116ra5.
PMID: 22238333
Recent studies have indicated that a significant survival advantage is conferred to patients with gliomas whose lesions harbor mutations in the genes isocitrate dehydrogenase 1 and 2 (IDH1/2). IDH1/2 mutations...